Earnings Releases·Nov 9, 2026, 4:13 PM ET

Harrow — Third Quarter 2026 Earnings Summary

Total revenue reached $99.3 million, a 41% sequential and 39% year-over-year increase, driven by 62% year-over-year growth in branded revenue to $83.5 million.
GAAP net income was $9.8 million, including a $5.0 million litigation settlement gain, while Adjusted EBITDA was $21.2 million, a significant improvement from the $1.2 million loss in Q2 2026.
Full-year 2026 Adjusted EBITDA guidance was lowered to more than $40 million from the prior range of $80 million to $100 million to reflect first-half operating shortfalls and increased spending on G-MELT and TYRVAYA integration; full-year revenue guidance of $350 million to $365 million was reaffirmed.
The company completed the acquisition of TYRVAYA on October 1, 2026, and launched HarrowRx on November 1, 2026, while VEVYE, IHEEZO, and TRIESENCE all reported record or strong sequential revenue growth.
The IHEEZO QUELL study failed to meet its primary non-inferiority endpoint, though secondary findings indicated lower cumulative pain and fewer adverse events, with results to be presented in January 2027.